Reproducibility and repeatability of assessment of myocardial light chain amyloidosis burden using 18 F-florbetapir PET/CT
CONCLUSION: PLOA can lead to visual and organ threatening complications. Accurate diagnosis is required for further diagnostic and therapeutic procedures and to counteract potential local and systemic complications. Interindividual differences in the course have to be considered. PMID: 31968364 [PubMed - in process]
To determine the diagnostic delay in patients with wild-type transthyretin cardiac amyloiodosis (ATTRwt). To determine the clinical and echocardiogtraphic characteristics of patients with an early and a late diagnosis and to study the suspected diagnoses and identification of diagnostic “red flags” before the ATTRwt diagnosis was established.
Multiple myeloma (MM) is the most common indication for high dose chemotherapy and autologous hematopoietic stem cell transplantation (ASCT). In addition, patients with immunoglobulin light-chain amyloidosis (AL), a related plasma cell disorder, often benefit from ASCT. Objectives: We aimed to compare baseline demographics, peri-transplant mortality, and the incidence of febrile neutropenia and bacteremia between an outpatient transplant cohort at one institution and an inpatient cohort at a second institution.
Deep and durable hematologic remissions following RA-ASCT are associated with improved organ function and extended overall survival in AL amyloidosis. While depth of hematologic response by standard criteria are important, this study assessed additional factors that influence RR and time to RR.
Autologous stem cell transplantation (ASCT) remains an effective treatment option for many patients with systemic AL amyloidosis (AL). However, the decision to utilize maintenance therapy following ASCT remains controversial and largely unexplored. Furthermore, the growing relevance of cytogenetics in AL may help dictate this maintenance decision as well. It is also relevant to note the emergence of novel targeted therapy options for AL patients, including the plasma cell monoclonal antibody daratumumab, that offer an exciting option in combination therapies with ASCT.
Body surface area-based dosing of melphalan prior to AHCT for MM and AL patients causes inter-patient variability in exposure measured by area under the curve (AUC). Higher AUC is associated with increased toxicity, but prolonged survival (Shaw et al., BBMT 2012). Using Evomela (PGF-MEL, Acrotech Biopharma LLC), a more stable and possibly less toxic intravenous formulation of melphalan, we examined the feasibility of PK-directed dosing to individualize and optimize therapy.
ConclusionEarly diagnosis and treatment of laryngeal amyloidosis may reduce the recurrence of the disease. Regular follow-up is necessary to find any recurrence.
ConclusionsCompared to general population the adjusted prevalence of CTS is higher among elderly men with ATTR; CTS is a prognostic marker in ATTR, independently of cardiac involvement, and precedes CA diagnosis by 5 –9 years. The awareness of this association and time delay offers the possibility of an early pre‐clinical ATTR‐CA diagnosis.
The American Society of Nuclear Cardiology (ASNC) and the American Society...Read more on AuntMinnie.comRelated Reading: ASNC releases directive on cardiac amyloidosis imaging Imaging groups oppose cuts in myocardial PET rates ACC, ASE release echocardiography training guidance ASNC names Beanlands as president